Meet Jessica Kovall

Jessica Kovall, PA-C CV

Arcadia University 05/2011- 05/2013

  • Master of Medical Science in Physician Assistant Studies
  • Glenside, Pennsylvania


The College at Brockport, State University of New York 08/2004- 05/2008

  • Bachelor of Science in Biological Sciences, Minor in Chemistry, Pre-Medicine Concentration

  • Accomplishments: Magna Cum Laude, Dean’s List, Alphi Chi- National Honor Society in Academics, Beta Beta Beta- National Honor Society in Biology, SUNY Brockport Honor’s Program
  • Awards: Academic Student Athlete


PROFESSIONAL MEMBERSHIPS AND CERTIFICATIONS

  • California State License April 2018 - February 2024
  • DEA June 2016 - December 2021
  • Hawaii State License May 2015- Current
  • Maryland State License August 2014- June 2015
  • Certified DOT Medical Examiner by the FMCSA July 2014- July 2024
  • New York State License August 2013- July 2016
  • Certified by the National Commission on Certification of Physician Assistants May 2013
  • BLS and ACLS Certification – American Heart Association Active: April 2012 – Current
  • Good Clinical Practice Expires: July 2024
Jessica Kovall, PA-C

More About Jessica Kovall, PA-C

GW Research, Inc. Gastroenterology: 353 Church Ave. Chula Vista, CA 91910

July 2018 – current

Physicians’ assistant working in busy gastroenterology clinic, providing outpatient consultation, follow up services, and entering patients into drug trials. Involved in variety of GI related patient care with detailed history, physical examinations, development and implementation of treatment plans, prescription of medications, ordering and interpretation of laboratory tests and diagnostic studies. Evaluating and treating common GI complaints and managing chronic GI conditions (i.e.: IBS, IBD, Hepatitis B & C, Colitis, Cirrhosis, NASH, Gastroparesis.) Educating patients, conducting pre-op exams and follow up for GI procedures.


Hawaii Gastroenterology Specialists LLC, Gastroenterology; Aiea HI

June 07, 2016- July 2018

· Efficiently and accurately diagnose and treat common gastrointestinal complaints and manage chronic gastrointestinal conditions (i.e.: IBS, IBD, Hepatitis B & C, Colitis, Cirrhosis.)

· Examine, diagnose, and treat 18-24 adult patients daily, in a busy outpatient clinic

· Rapidly became expert user of GMED EMR system, reputation for thorough charts

· Provide exceptional care showcased through positive feedback/patient satisfaction and multiple reviews, resulting in a high degree of patient loyalty

· Responsible for investigating and resolving patient complaints/incidents in a proactive and professional manner

· Communicate and collaborate with gastrointestinal team, including medical assistants, office managers, ultrasound technician and five supervising physicians

· Communicate and collaborate with referring physicians, specialty physicians, pharmacists, and radiologists

The Medical Corner, Urgent Care; Kailua HI

October 2015- July 2016

· Examine, diagnose, and treat 20-30 patients/day (all ages), as solo provider

· Perform minor procedures including suturing, wound care, minor orthopedic injury assessment and treatment, splint application, foreign body removal, nail excision, I&D of abscess and more

· Served as the local community college health provider.

· Experience with eye exam using fluorescein and woods light, pelvic examinations, and microscopic examination with KOH prep.

· Certified to perform DOT physicals; also experience with Occupational Health and Workers Compensation

Comp Health Travel, Urgent Care

Kaiser Permanente Hawaii, July 2015-September 2015

· Examine, diagnose, and treat 20-30 patients/day (all ages), as solo provider

· Perform minor procedures including suturing, wound care, minor orthopedic injury assessment and treatment, splint application, foreign body removal, nail excision, I&D of abscess and more

· Served as the local community college health provider.

· Experience with eye exam using fluorescein and woods light, pelvic examinations, and microscopic examination with KOH prep.


Righttime Medical Care, Urgent Care; Annapolis, MD

November 2014- June 2015

· Examine, diagnose, and treat 30-40 patients/day (all ages), as solo provider, and 40-80 patients/day (all ages), collaborating with another provider

· Perform minor procedures including suturing, wound care, minor orthopedic injury assessment and treatment, splint application, foreign body removal, nail excision, I&D of abscess and more

· Trained as provider for HeadFirst Concussion Clinic, one of the nation’s largest concussion clinics

· Recommendations of subspecialists, consultants, referrals to the ER

North Country Urgent Care, Urgent Care; Watertown, NY

Supervising physician: Dr. Walter Minaert

August 2013- November 2014

· Examine, diagnose, and treat 20-40 patients/day (all ages), as solo provider

· Perform minor procedures including suturing, wound care, minor orthopedic injury assessment and treatment, splint application, foreign body removal, nail excision, I&D of abscess and more

· Served as the local community college health provider.

· Experience with eye exam using fluorescein and woods light, pelvic examinations, and microscopic examination with KOH prep.

· Certified to perform DOT physicals; also experience with Occupational Health and Workers Compensation

CLINICAL RESEARCH

Sub-Investigator: Braintree: A Safety and Efficacy Comparison of BLI4700 Bowel Preparation

versus an FDA-approved Comparator in Adult Subjects prior to Colonoscopy July 2018 – November 2018 (12 Screened,12 Randomized) Top Enroller.


Sub-Investigator: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy of Tradipitant in Relieving Symptoms of Gastroparesis February 2018 (6 Screened)



Sub-Investigator: Allergan, RLM-MD-02: A 12-week, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Relamorelin in Patients with Diabetic Gastroparesis July March 2018 (23 Screened)


Sub-Investigator: Allergan, RLM-MD-03: A 46-week, Double-blind, Placebo-controlled, Phase 3 Study with a 6-week Randomized-withdrawal Period to Evaluate the Safety and Efficacy of Relamorelin in Patients with Diabetic Gastroparesis July 2018 (3 randomized rollovers)


Sub-Investigator: Allergan, RLM-MD-04: A 52-week, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Relamorelin in Patients with Diabetic Gastroparesis June 2018 (10 screened)


Sub-Investigator: MCP-103-312: A Phase 3b, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial of Linaclotide 290 µg Administered Orally for 12 Weeks in Patients with Irritable Bowel Syndrome with Constipation July 2018 (30 screened, 16 randomized)


Sub-Investigator: Intercept, 747-303: Phase 3, Double-Blind, Randomized, Long-Term, Placebo-Controlled, Multicenter Study Evaluating the Safety and Efficacy of Obeticholic Acid in Subjects with Nonalcoholic Steatohepatis. December 2016– ongoing (30 screened, 6 Randomized) NCT02548351


Sub-Investigator: Ironwood Pharmaceuticals: C3718-301: A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Trial of Oral IW-3718 Administered to Patients with Gastroesophageal Reflux Disease while receiving Proton Pump Inhibitors September 2018 – (43 screened, 10 randomized)


Sub-Investigator: Protocol G28-006: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy, Durability, Safety, and Tolerability of RP-G28 in Patients with Lactose Intolerance August 2018 – 2019 (22 screened)


Sub-Investigator: 3152-301-002 - AURORA: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects with Nonalcoholic November 2018 – 2020 (20 screened)


Sub-Investigator: VP-VLY-686-3301: VP-VLY-686-3301Vanda: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study to Assess the Efficacy of Tradipitant in Relieving Symptoms of Gastroparesis November 2019 – ongoing (52 screened, 15 randomized)


Sub-Investigator: EE-301: A Phase 3, Randomized, Double-Blind, Two-Phase, Multicenter Study to Evaluate the Efficacy and Safety of Vonoprazan 20 mg Compared to Lansoprazole 30 mg for Healing in Patients with Erosive Esophagitis and to Evaluate the Efficacy and Safety of Vonoprazan (10 mg and 20 mg) Compared to Lansoprazole 15 mg for the Maintenance of Healing in Patients with Healed Erosive Esophagitis November 2019 – October 2021 (58 screened, 24 randomized)


Sub-Investigator: 2018-10, An Evaluation of a Multi-target Stool DNA (mt-sDNA) Test, Cologuard, for CRC Screening in Individuals Aged 45-49 and at Average Risk for Development of Colorectal Cancer: Act Now October 2019 (47 screened)


Sub-Investigator: PBGD 1001, An Open Label, Multicenter Study to Assess the Efficacy and Safety of Salix Probiotic Blend in Patients with Functional Gastrointestinal Disturbances. December 2019

(20 Screened, 20 randomized)


Sub-Investigator: Genentech, Inc. GC41033A Phase II, randomized, parallel-group, double-blind, placebo-controlled, multicenter study to evaluate the efficacy, safety, and pharmacokinetics of bfkb8488a compared with placebo in patients with non-alcoholic steatohepatitis, February 2019-ongoing


Sub-Investigator: Arena Pharmaceuticals, APD371 202, A Phase 2, Multi Center, Randomized, Double Blind, Placebo Controlled Parallel Group Study to Evaluate the Safety, Tolerability, and Efficacy of Olorinab in Subjects with Irritable Bowel Syndrome Experiencing Abdominal Pain. February 2019- July 2021 (8 screened, 1 randomized)


Sub-Investigator: Braintree, BLI4900-302, A Safety and Efficacy Comparison of BLI4900 Bowel Preparation versus an FDA-approved Comparator in Adult Subjects prior to Colonoscopy, February 2019 (31 screened, 31 randomized)


Sub-Investigator: Allakos, Inc., AK002-019: A Prospective Study to Identify the Incidence of Eosinophilic Gastrointestinal Diseases and Elevated Tissue Mast Cells among Patients with Chronic Gastrointestinal Symptoms. March 2020- December 2020 (24 screened, 23 randomized)


Sub-Investigator: Exact Sciences Act Fast 2018-07, Blood and Stool Sample Collection in Subjects with a Diagnosis of Colorectal Cancer or Colorectal Lesion, April 2019-ongoing (15 screened)


Sub-Investigator: Allakos Study AK002-016: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of AK002 in Patients with Moderately to Severely Active Eosinophilic Gastritis and/or Eosinophilic Duodenitis (formerly referred to as Eosinophilic Gastroenteritis) Who Have an Inadequate Response with Lost response to, or Were Intolerant to Standard Therapies, December 2020- ongoing (31 Screened, 8 Randomized)


Sub-Investigator: Exact Science 2019-01, Clinical Validation of An Optimized Multi-Target Stool DNA (mt-sDNA 2.0) Test, for Colorectal Cancer Screening “Blue-C” Feb 2021- ongoing (134 screened)


Sub-Investigator: Neurogastrx NG101-201: A Phase 2 Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of the Safety and Efficacy of NG101 Administered Orally to Patients with Gastroparesis. May 2021- ongoing (16 screened, 1 randomized)



Sub-Investigator: NERD-201: A Phase 2, Randomized, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of Vonoprazan 10 mg, 20 mg and 40 mg Compared to Placebo for Relief of Episodic Heartburn in Subjects with Symptomatic Non-Erosive Gastroesophageal Reflux Disease. March 2021- February 2022 (33 screened, 8 randomized)


Sub-Investigator: Allakos Study AK002-016X: A Phase 3, Multicenter, Open-Label, Extension Study to Evaluate the Efficacy and Safety of AK002 in Patients That were Previously Enrolled in AK002-016 or AK002-012 studies and have Eosinophilic Gastritis and/or Eosinophilic Duodenitis (formerly referred to as Eosinophilic Gastroenteritis). July 2021-ongoing (8 screened, 7 randomized)


Sub-Investigator: ION224-CS2: An Adaptive Two-Part Phase 2, Multi-Center, Randomized, Double Blind, Placebo-Controlled Study to Assess the Safety, Efficacy, and Pharmacokinetics of Multiple Doses of ION224 Administered Once Monthly in Adult Subjects with Confirmed Non-Alcoholic Steatohepatitis. July 2022-ongoing (8 screened, 2 randomized)


Sub-Investigator: Allakos Study AK002-021: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of AK002 in Patients with Moderately to Severely Active Eosinophilic Duodenitis who have an Inadequate Response with Lost Response to, or were Intolerant to Standard Therapies. July 2021-ongoing (17screened, 3 randomized)


Sub-Investigator: NERD-301: A Phase 3, Randomized, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of Vonoprazan 10 and 20 mg Compared to Placebo for Relief of Heartburn in Subjects with Symptomatic Non-Erosive Gastroesophageal Reflux Disease (NERD) After 4 Weeks and to Evaluate the Efficacy and Safety of Vonoprazan 10 and 20 mg for Relief of Heartburn in Subjects with NERD After 6 Months. February 2022-ongoing (12 screened, 5 randomized)


Sub-Investigator: Citius, 143-11351-202: A Randomized, Dose-Ranging, Double Blind Study to Demonstrate the Safety and Efficacy of a CITI-002 Cream in the Seven Day Twice-Daily Treatment of Grade II or III Hemorrhoids. ongoin

admin none 9:00 am-4:00 pm 9:00 am-4:00 pm 9:00 am-4:00 pm 9:00 am-4:00 pm 9:00 am-4:00 pm Closed Closed # # #